{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:18:58Z","timestamp":1788783538749,"version":"build-2803163510"},"reference-count":10,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T00:00:00Z","timestamp":1329868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2012,6]]},"abstract":"ABSTRACT<\/jats:title>Purpose<\/jats:title>The Food and Drug Administration (FDA) conducted a quality assessment of the Adverse Drug Events Spontaneous Triggered Event Reporting (ASTER) pilot study, which represented the FDA's first experience with the receipt of electronic health record (EHR)\u2013triggered adverse event reports. The EHR\u2010triggered adverse event reports from ASTER were evaluated for their utility in conducting FDA's pharmacovigilance work. FDA is sharing these findings to assist others who are pursuing the use of patient EHR data for electronic adverse event identification and reporting.<\/jats:p><\/jats:sec>Methods<\/jats:title>ASTER pilot study reports were identified from the FDA Adverse Event Reporting System database, then reviewed and assessed.<\/jats:p><\/jats:sec>Results<\/jats:title>Demographic and other objective data that can be easily derived from EHRs were both present in the submitted reports and relevant to the reported adverse drug event (ADE), but other data, such as an informative description of the ADE, dates that support a temporal relationship between the product and the event, and relevant laboratory data, were often either conflicting or lacking. Most of the ADEs captured in the ASTER pilot and reported to FDA are known events (i.e. included in product labeling) for the suspect drugs.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Triggered adverse event reporting from patient EHRs is a potentially valuable source of postmarketing safety information, especially for known adverse events. Attention to quality is needed to ensure that the data generated from EHR\u2010triggered ADE reporting systems are relevant to the reported adverse events so that the FDA and others engaged in pharmacovigilance can fully utilize these reports. Published 2012. This article is a US Government work and is in the public domain in the USA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3223","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T13:40:54Z","timestamp":1329918054000},"page":"565-570","source":"Crossref","is-referenced-by-count":24,"title":["Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration"],"prefix":"10.1002","volume":"21","author":[{"given":"Sonja","family":"Brajovic","sequence":"first","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Piazza\u2010Hepp","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette","family":"Swartz","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Dal Pan","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-060309-164311"},{"key":"e_1_2_9_3_1","unstructured":"FDA guidance for industry onGood Pharmacovigilance Practices and Pharmacoepidemiologic Assessment U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) March2005;http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/UCM126834.pdf(accessed 16. December 2011)"},{"key":"e_1_2_9_4_1","unstructured":"MedWatch form can be downloaded at: MedWatch the FDA safety information and adverse event reporting program \u2013 reporting serious problems to FDAhttp:\/\/www.fda.gov\/Safety\/MedWatch\/HowToReport\/DownloadForms\/default.htm(accessed 16. December 2011)"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1991"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2027"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.205010"},{"key":"e_1_2_9_8_1","unstructured":"Adverse Event Reporting System (AERS) http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm(accessed 16. December 2011)"},{"key":"e_1_2_9_9_1","unstructured":"FDA guidance for industry onPostmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August1997;http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071981.pdf(accessed 16. December 2011)"},{"key":"e_1_2_9_10_1","unstructured":"Code of Federal Regulations Title 21 Section 314.80 Postmarketing reporting of adverse drug experiences (a) Definitions http:\/\/ecfr.gpoaccess.gov\/cgi\/t\/text\/text\u2010idx?c=ecfr&sid=11664364f933ee87a425e1d687fd9496&rgn=div8&view=text&node=21:5.0.1.1.4.2.1.11&idno=21(accessed 16. December 2011)"},{"key":"e_1_2_9_11_1","volume-title":"Realizing the full potential of health information technology to improve healthcare for Americans: the path forward","year":"2010"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3223","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T06:43:58Z","timestamp":1696920238000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,22]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/pds.3223"],"URL":"https:\/\/doi.org\/10.1002\/pds.3223","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,22]]}}}